Loading stock data…
$135.07
Apogee Therapeutics, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$91.64M↓ | -$82.77M↓ | -$78.06M↓ | -$71.28M↑ | -$73.17M |
| Net Income | -$85.85M↓ | -$74.11M↓ | -$69.39M↓ | -$65.02M↑ | -$66.10M |
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for...